Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
Phase 1
Withdrawn
- Conditions
- Obesity
- Registration Number
- NCT00376285
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- BMI of 30-40 kg/m2
Exclusion Criteria
- Women of childbearing potential
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Toleration and safety
- Secondary Outcome Measures
Name Time Method Efficacy biomarkers, serum lipids